# data[].attributes.title
Repository of Monoclonal Antibodies (RoMA) against Hamster and Guinea Pig Proteins

# data[].attributes.funder_divisions[]
National Institute of Allergy and Infectious Diseases (NIAID)

# data[].attributes.abstract
Small animal models are ideal to study diverse infectious and inflammatory diseases with mice being a widely used model system due to the well-characterized immune response and availability of reagents. Yet, the drawbacks of the mouse animal model are that it does not mimic many diseases due to the lack of clinical symptoms, differences in immune activation, and non-susceptible to infection of many pathogens. In fact, ferrets, Guinea pigs, and hamsters are a more suited animal model for numerous infectious pathogens including bat coronaviruses (SARS-CoV and SARS-CoV-2), influenza virus, and respiratory syncytial virus, respectively; yet, the lack of reagents that define the immune and inflammatory responses in ferrets, Guinea pigs, and hamsters prevent their utilization to comprehensively understand disease pathology and effectiveness of therapeutics and vaccines. Thus, there is a severe reagent gap for monoclonal antibodies against immune and inflammatory markers of ferrets, Guinea pigs, and hamsters to use these animal models in infectious disease studies. The main objective of the R24 application is to create a Repository of Monoclonal Antibodies (RoMA) for use in small animal models for evaluating infectious and inflammatory disorders fulfilling a major reagent gap in the scientific community. We hypothesize that reagents that monitor the immune response in hamster and Guinea pig model systems will be widely used in infectious disease model systems to predict disease progression and effectiveness of vaccines and therapeutics in human disease. A panel of monoclonal antibodies will be generated upon completion of the following aims: Aim 1: Develop antibodies targeting hamster and guinea pig surface markers on the respective immune cells. The hamster has become an excellent model for respiratory pathogens including SARS-corona viruses, Rift Valley fever, and Clostridium difficile; while the Guinea pig animal model provides insight into numerous infection and transmission models such as influenza virus and herpesviruses. Aim 2: Identify and generate monoclonal antibodies to hamster and guinea pig immune cell activation markers. We plan to identify and generate monoclonal antibodies to activated immune cell immune markers of hamster and Guinea pigs. These activated biomarkers will consist of previously characterized human and mouse orthologs that likely function in immune regulation. We expect to generate a total of 50 monoclonal antibodies (25 anti-hamster and 25 anti-Guinea pig proteins) over the 5-year grant period that will be available to the scientific community. These antibodies will be essential for evaluating the immune and inflammatory responses in the hamster and Guinea pig animal models.

# data[].attributes.keywords[]
United States National Institutes of Health

# data[].attributes.title
Investigating the role of T cells in promoting post-acute memory deficits after COVID-19 in mice

# data[].attributes.funder_divisions[]
National Institute of Allergy and Infectious Diseases (NIAID)

# data[].attributes.abstract
Millions of individuals in the United States suffer from post-acute symptoms of COVID-19 (PASC), many of which are neurological in origin. Although SARS-CoV-2 does not cause widespread infection of the central nervous system (CNS), significant neuroinflammation, decreased adult neurogenesis, alterations in synaptic proteins, decreased total brain volume, and poor performance on tests of learning and memory have all been observed in COVID-19 patients. However, the mechanisms by which a respiratory virus is causing persistent neurological dysfunction are not well understood. Studies of PASC patients identified ongoing dysregulation of T cell responses in the serum and imaging studies confirmed that PASC patients have activated T cells in the CNS. Homeostatic T cells in the meninges are known to influence learning, memory, and anxiety-like behavior through the secretion of cytokines, however the impact of T cells on neurological symptoms after COVID-19 is unknown. Thus, I hypothesize that systemic inflammation promotes recruitment of antigen-specific T cells to the CNS after SARS-CoV-2 infection, and these cells contribute to persistent deficits in learning and memory via secretion of cytokines and other pro-inflammatory mediators. To investigate this, I will utilize my recently developed mouse model of neurological dysfunction after COVID-19, in which intranasal infection of wild-type mice with SARS-CoV-2 causes robust infection of the respiratory tract, but not the CNS, post-acute memory deficits, loss of hippocampal neurogenesis, and increased pro-inflammatory cytokines in the CNS. Preliminary data found that CD4+ T cells are recruited to the meningeal dura after infection and promote post-acute memory deficits as determined via the Novel Object recognition test. In the K99 phase of this proposal, (Aim 1) I will investigate the phenotype of CD4+ T cells in the CNS after SARS-CoV-2 infection and determine how cytokines secreted by CD4+ T cells may contribute to memory deficits using a behavioral test battery and investigation of neurogenesis and tri-synaptic circuit function. In Aim 2, I will test if T cell priming and differentiation impact pathogenicity in the CNS after COVID-19 by first, determining if antigen specificity is required for recruitment to and effector functions in the CNS and second, investigating which CD4+ T cell effector subset is driving post-acute memory deficits. In the R00 phase, I will utilize a previously established murine model of breakthrough vaccination to investigate how priming of CD4+ T cells in the periphery influences differentiation into a pathogenic CD4+ effector subset. In Aim 3, I will explore how severe, systemic inflammation may be driving recruitment of these pathogenic T cells to the CNS and which chemokine: receptor pairs are critical for this process. Combined, this project will determine the mechanisms by which pathogenic CD4+ T cells are recruited to the CNS after COVID-19 and how they promote post-acute learning and memory deficits. These data could identify fundamental mechanisms by which immunity to viral infections controls neurological function and potential druggable targets for treatment of PASC.

# data[].attributes.title
A biochemical roadmap of exercise signal

# data[].attributes.abstract
Exercise is an effective intervention for both the prevention and treatment of cardiometabolic diseases, but the mechanistic underpinnings of the health benefits of exercise remain incompletely defined. Recent work highlights the importance of inter-organ circuits in mediating healthful exercise responses. We identified β- aminoisobutyric acid (BAIBA) as a novel small molecule “myokine” that increases the expression of brown adipocyte-specific genes in vitro and improves glucose disposal and decreases weight gain in mice. In humans, plasma BAIBA concentrations are increased with chronic exercise and demonstrate a strong inverse association with metabolic risk factors. Further, related efforts by our group have positioned us as leaders in characterizing within- and between-tissue molecular responses to exercise and dietary interventions. These experiences, coupled with the high translational relevance of the research problem, motivated our participation in the MoTrPAC initiative. Our team was built upon existing collaborations between Duke, Harvard and the Broad Institute with complementary strengths in metabolomics and proteomics technologies and decades of experience in cardiometabolic research. To date, we have provided a deep menu of analytical tools for targeted and non-targeted metabolomics, protein profiling, and the analysis of key protein post-translational modifications. Group members have been deeply involved in the animal and pre-COVID biochemical profiling efforts, in collaborations with other Chemical Analysis Sites (CAS) and the Bioinformatics Core to harmonize workflows, and in the working groups necessary to integrate the data. We have also played key roles in associated scholarly activities and in developing the next generation of translational investigators focused on exercise science. An additional distinction of our team is the ability to integrate new findings from MoTrPAC with ongoing genomic, proteomic and metabolomic analyses in large human cohorts and other exercise studies led by our investigators. We hypothesize that integrating the metabolomic and proteomic profiles of human tissues and blood during exercise with genetics and detailed human phenotyping will provide novel insights into the interorgan circuits and within-organ responses that mediate its salutary effects. We are deeply committed to the notion that all data generated by this multi-disciplinary consortium will be made rapidly available to the scientific community.

# data[].attributes.title
Respiratory pathogen-specific T cell signatures following vaccination, natural infection, and treatment

# data[].attributes.funder_divisions[]
National Institute of Allergy and Infectious Diseases (NIAID)

# data[].attributes.abstract
– Overall  The La Jolla HIPC team will focus on pathogens causing infectious diseases of the upper and lower respiratory tract that lead to substantial mortality and morbidity. Our approach is unique and innovative, as it focuses on defining immune signatures (IMS) of antigen-specific CD4 and CD8 T cells generated in response to natural infection with important respiratory pathogens such as SARS-CoV-2, Common Cold Coronaviruses (CCC), influenza, Respiratory Syncytial Virus (RSV) and Mycobacterium tuberculosis (Mtb). Likewise, our Program will investigate IMS of antigen-specific T cells generated following vaccination against a diverse array of pathogens in different platforms like attenuated pathogens (BCG, yellow fever (YF)), purified proteins (acellular Bordetella pertussis (PT) vaccines), viral vectors (J&J, SARS-CoV-2) and mRNA (Moderna and Pfizer).  In Project 1, we will perform longitudinal analysis to determine persistence and plasticity of antigen-specific T cell responses following natural SARS-CoV-2 infection and vaccination. We will study T cell responses specific to SARS-CoV-2 following vaccination with different vaccine platforms in previously-unvaccinated donors, and in a longitudinal cohort of vaccinated individuals previously naturally-infected with SARS-CoV-2. In parallel studies, we will analyze T cell responses to SARS-CoV-2 in naturally-infected unvaccinated donors. We will also analyze T cell responses in two previously-enrolled cohorts who received YF and PT vaccinations; in both cohorts the natural evolution and persistence of T cell responses to CCC viruses will be investigated.  In Project 2, we will perform longitudinal analysis of the IMS of Mtb-specific T cells. Here, we will build on our progress made during the previous HIPC funding period to characterize the IMS associated with latent and active TB disease as well as BCG vaccination. Specifically, we will characterize the longitudinal IMS of both active and latent TB during treatment. In parallel, we will characterize the longitudinal IMS of adults (re)vaccinated with BCG, and characterize the IMS of Mtb-specific T cells in the lung.  In Project 3, we will determine the molecular properties of pathogen-specific lung tissue-resident memory T cells (TRM). Our goal is to establish a single-cell atlas of the transcriptome, epigenome, and T cell receptor (TCR) of antigen-specific lung TRM targeting common pathogens that infects the lungs such as: viral (influenza, RSV, para influenza, meta pneumovirus, SARS-CoV-2, CCC), bacterial (pneumococcus, PT, Mtb) and fungal pathogens. The longitudinal study design will enable assessment of plasticity and persistence of lung TRM cells following natural infection and vaccination. The synergy between Projects will allow the generation of cross- comparable large-scale single-cell T cell signatures for respiratory pathogens/vaccines.

# data[].attributes.keywords[]
National Institute of Allergy and Infectious Disease

# data[].attributes.title
International Symposium on Medical Robotics

# data[].attributes.funder_divisions[]
National Institute of Biomedical Imaging and Bioengineering (NIBIB)

# data[].attributes.abstract
Enter the text here that is the new abstract information for your application. This section must be no longer than 30 lines of text. SUMMARY Significance, timeliness and rationale. NIBIB’s mission is to transform through engineering the understanding of disease and its prevention, detection, diagnosis, and treatment. Life would not be possible without liquid crystalline (LC) order. The most celebrated example is the unique combination of flexibility and confining ability of cell membranes which is possible because lipids cooperatively aggregate into a lamellar LC phase in water. Many viruses, e.g., SARS-CoV-2, are enveloped in a lipid membrane and they may employ LC order for packing their nucleic acid cargo. Non-biological LCs have turned out to be sensitive in detecting and reporting on the presence of pathogens and toxins, making them highly interesting for autonomous bio-/chemosensors. LC formation is thus an integral component of what keeps us healthy, and they are emerging as a powerful tool for detecting disease agents. Although this connection is long known, it has until now been researched only marginally, constituting an under-explored opportunity in addressing societal needs. Today, the international LC research community is undergoing a rebirth, fully embracing these aspects. Interdisciplinary crossovers where LC science meets biological, life and pharmaceutical sciences, and engineering and materials science, play a groundbreaking role in leveraging the opportunities. Additional impact on the core fields of the NIH-NIBIB mission comes from, e.g., the exploration of LC elastomers in soft actuators or implants in the human body. Objective. Gordon Research Conference (GRC) and Gordon Research Seminar (GRS) in Liquid Crystals, 2025: “Uniting disciplines for global challenges: Liquid crystals as active and learning materials” to take place July 6-11th 2025 (GRS July 5-6, 2025) at the Southern New Hampshire University, Manchester, NH, US. The joint meetings will bring together US and international researchers at the forefront of today’s vibrant LC science, spanning its full breadth and connecting academia, industry and military labs, early career and established researchers, and harnessing every opportunity to promote scientific discussions and encourage collaboration between speakers, discussing leaders and participants. Approach. 23 prominent speakers have confirmed our invitations to present unpublished cutting-edge research. Our goal is to promote the participation of students, postdocs, and scholars at an early stage of their careers. We seek to promote scientific discussion among all participants who will fuel the future of Liquid Crystal Science in biomedical and biotechnology applications. Academic speakers are complemented by 2 industry and 2 military research lab speakers. Additionally, 5 speaker slots will be given to outstanding scientists selected from submitted poster abstracts. To further strengthen the voice of young researchers, the GRC is preceded by the GRS, catering only to students and post-docs and providing mentoring and career advice. During the GRC, young scientists will be given priority in all scientific discussions.

# data[].attributes.keywords[]
National Institute of Biomedical Imaging and Bioengineering

# data[].attributes.keywords[]
United States National Institutes of Health

# data[].attributes.title
Molecular profiles for mortality risk and longevity: a multiomics approach

# data[].attributes.awardee_organization.name
HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH

# data[].attributes.abstract
The US life expectancy experienced a generally upward trend over the past few decades; however, in recent years, it has seen a decline. This decline cannot be solely attributed to the excess mortality caused by COVID- 19 but also to an increased death rate from other leading causes (e.g., heart disease, cancer, and stroke). The biological mechanisms that underlie aging process and mortality in humans are multifactorial and remain poorly understood. Although multiple genetic variants have been linked to lifespan in model organisms, many of these genes do not exhibit significant variation in human populations. The heritability of human lifespan also appears to be relatively low. One possible explanation for lack of significant loci and low heritability is the complexity of survival as a phenotype, which involves multiple biological processes, environmental influences, and chance. The stochastic component of survival may dilute the genetic influence on the time-to-death phenotype. Consequently, a substantial mechanistic gap exists between genotype and mortality. The proposed K99/R00 project aims to utilize plasma metabolomic and proteomics profile to bridge this gap and comprehensively investigate the relationship between genes, proteins, metabolites, and mortality risk. To achieve this goal, Dr. Fenglei Wang will incorporate data from multiple sources, including the Nurses’ Health Study (NSH), NHSII, Health Professionals Follow-up Study (HPFS), Hispanic Community Health Study/Study of Latinos (HCHS/ SOL), VITamin D Omega3 TriAL (VITAL), UK Biobank (UKB), and eQTLGen. In Aim 1 (K99), Dr. Wang will determine genetic factors that influence a plasma metabolomic signature, previously developed by him, which has the potential to predict all-cause mortality. He will also evaluate the causal relationship between the metabolomic signature and four diseases that are major causes of death. In Aim 2 (R00), Dr. Wang will construct a plasma proteomic signature capable of predicting all-cause mortality and identify genetic factors influencing the proteomic signature. Then he will compare the influential genetic factors identified for the proteomic signature to those for the metabolomic signature. In Aim 3 (R00), Dr. Wang will conduct plasma proteomic profiling in a nested case-control study to examine the relationship between longitudinal changes in plasma metabolomic and proteomic profiles and healthy longevity. Findings from this project may improve our understanding of the molecular profiles associated with the aging process and mortality, and inform potential interventions for improving health outcomes and extending human lifespan. Dr. Wang has assembled a strong mentoring team to provide expertise in aging research and training in genetics, proteomics, and multi-omics integration. The new skills will complement his current expertise in nutritional epidemiology and metabolomic research. His outlined training plan will provide the necessary knowledge and skills for Dr. Wang to advance towards his career goal of becoming an independent researcher who specializes in the application of multi-omics approach to study nutrition and healthy aging.

# data[].attributes.keywords[]
Hispanic Community Health Study/Study of Latinos

# data[].attributes.title
East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional Consortium

# data[].attributes.funder_divisions[]
National Institute of Allergy and Infectious Diseases (NIAID)

# data[].attributes.abstract
Project Summary/Abstract: Our primary goal continues to be the provision of answers to questions that clinicians, governments, programs and international organizations consider central to the evolution and sustainability of their long term HIV care and treatment strategies for achieving the UNAIDS 2030 targets of 95-95-95 in the midst of the SARS-CoV-2 pandemic and changes in public health funding priorities. Our central hypothesis is that retention in the HIV care cascade and treatment outcomes are influenced by patient-level demographic, clinical, developmental, and behavioral factors, as well as, factors within the ambient health care and broader contextual environment. We will leverage our strengths, including robust working relationships with HIV treatment programs, a substantial harmonized regional database, plus broad experience in sampling-based methodologies and novel analytical approaches. Over the course of this research we will: SA-1: Describe movement through the HIV care cascade with a focus on identifying broader and health care environment contextual factors that influence optimal retention in care and viral suppression, in the face of global disruption due to the COVID-19 pandemic and changes in donor funding priorities. The Post COVID-19 Double-Sampling Cohort (Post COVID) will address the impact of broader contextual factors (COVID-19) while the Telehealth and Structural Adaptations project will address the impact of health care structure. SA-2: Examine the impact of developmental stage and behavioral factors on retention in the cascade and subsequent outcomes. The multiregional Adolescent and Young Adult Network of IeDEA (AYANI) and regional Measuring Adverse Pregnancy and Newborn Congenital Outcomes (MANGO) cohorts will assess the impact of developmental stage on the cascade, while the Syndemics cohort will address the impact of mental health on the cascade.SA- 3: Examine the immediate and long-term outcomes of people diagnosed with Tuberculosis (TB) with a focus on identifying and addressing factors associated with patient outcomes. The multiregional TB Sentinel Research Network (TB-SRN) will focus on understanding TB outcomes and long-term pulmonary complications including associated factors. SA-4: Explore the use of new technologies, including eHealth and machine (deep) learning to diagnose and manage HIV-associated cancers with a focus on Kaposi’s Sarcoma (KS) and Cervical Cancer. The KS Project will assess implementation of a Dermatology Telehealth Program and the Cervical Cancer Project will assess the implementation of cervical image capture with machine learning for cancer diagnoses and management. SA-5: Examine the epidemiology of NCD comorbidities and ART complications with a focus on the oldest and youngest-age groups affected by HIV. The multi-regional Sentinel Research Network (SRN) will address non-communicable diseases in people living with HIV (PLHIV) > 40 years and the regional MANGO Cohort will address complications of ART/HIV exposure on HIV-Exposed Infants.

# data[].attributes.title
East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional Consortium

# data[].attributes.funder_divisions[]
National Institute of Allergy and Infectious Diseases (NIAID)

# data[].attributes.abstract
Project Summary/Abstract: Our primary goal continues to be the provision of answers to questions that clinicians, governments, programs and international organizations consider central to the evolution and sustainability of their long term HIV care and treatment strategies for achieving the UNAIDS 2030 targets of 95-95-95 in the midst of the SARS-CoV-2 pandemic and changes in public health funding priorities. Our central hypothesis is that retention in the HIV care cascade and treatment outcomes are influenced by patient-level demographic, clinical, developmental, and behavioral factors, as well as, factors within the ambient health care and broader contextual environment. We will leverage our strengths, including robust working relationships with HIV treatment programs, a substantial harmonized regional database, plus broad experience in sampling-based methodologies and novel analytical approaches. Over the course of this research we will: SA-1: Describe movement through the HIV care cascade with a focus on identifying broader and health care environment contextual factors that influence optimal retention in care and viral suppression, in the face of global disruption due to the COVID-19 pandemic and changes in donor funding priorities. The Post COVID-19 Double-Sampling Cohort (Post COVID) will address the impact of broader contextual factors (COVID-19) while the Telehealth and Structural Adaptations project will address the impact of health care structure. SA-2: Examine the impact of developmental stage and behavioral factors on retention in the cascade and subsequent outcomes. The multiregional Adolescent and Young Adult Network of IeDEA (AYANI) and regional Measuring Adverse Pregnancy and Newborn Congenital Outcomes (MANGO) cohorts will assess the impact of developmental stage on the cascade, while the Syndemics cohort will address the impact of mental health on the cascade.SA- 3: Examine the immediate and long-term outcomes of people diagnosed with Tuberculosis (TB) with a focus on identifying and addressing factors associated with patient outcomes. The multiregional TB Sentinel Research Network (TB-SRN) will focus on understanding TB outcomes and long-term pulmonary complications including associated factors. SA-4: Explore the use of new technologies, including eHealth and machine (deep) learning to diagnose and manage HIV-associated cancers with a focus on Kaposi’s Sarcoma (KS) and Cervical Cancer. The KS Project will assess implementation of a Dermatology Telehealth Program and the Cervical Cancer Project will assess the implementation of cervical image capture with machine learning for cancer diagnoses and management. SA-5: Examine the epidemiology of NCD comorbidities and ART complications with a focus on the oldest and youngest-age groups affected by HIV. The multi-regional Sentinel Research Network (SRN) will address non-communicable diseases in people living with HIV (PLHIV) > 40 years and the regional MANGO Cohort will address complications of ART/HIV exposure on HIV-Exposed Infants.

# data[].attributes.title
East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional Consortium

# data[].attributes.funder_divisions[]
National Institute of Allergy and Infectious Diseases (NIAID)

# data[].attributes.abstract
Project Summary/Abstract: Our primary goal continues to be the provision of answers to questions that clinicians, governments, programs and international organizations consider central to the evolution and sustainability of their long term HIV care and treatment strategies for achieving the UNAIDS 2030 targets of 95-95-95 in the midst of the SARS-CoV-2 pandemic and changes in public health funding priorities. Our central hypothesis is that retention in the HIV care cascade and treatment outcomes are influenced by patient-level demographic, clinical, developmental, and behavioral factors, as well as, factors within the ambient health care and broader contextual environment. We will leverage our strengths, including robust working relationships with HIV treatment programs, a substantial harmonized regional database, plus broad experience in sampling-based methodologies and novel analytical approaches. Over the course of this research we will: SA-1: Describe movement through the HIV care cascade with a focus on identifying broader and health care environment contextual factors that influence optimal retention in care and viral suppression, in the face of global disruption due to the COVID-19 pandemic and changes in donor funding priorities. The Post COVID-19 Double-Sampling Cohort (Post COVID) will address the impact of broader contextual factors (COVID-19) while the Telehealth and Structural Adaptations project will address the impact of health care structure. SA-2: Examine the impact of developmental stage and behavioral factors on retention in the cascade and subsequent outcomes. The multiregional Adolescent and Young Adult Network of IeDEA (AYANI) and regional Measuring Adverse Pregnancy and Newborn Congenital Outcomes (MANGO) cohorts will assess the impact of developmental stage on the cascade, while the Syndemics cohort will address the impact of mental health on the cascade.SA- 3: Examine the immediate and long-term outcomes of people diagnosed with Tuberculosis (TB) with a focus on identifying and addressing factors associated with patient outcomes. The multiregional TB Sentinel Research Network (TB-SRN) will focus on understanding TB outcomes and long-term pulmonary complications including associated factors. SA-4: Explore the use of new technologies, including eHealth and machine (deep) learning to diagnose and manage HIV-associated cancers with a focus on Kaposi’s Sarcoma (KS) and Cervical Cancer. The KS Project will assess implementation of a Dermatology Telehealth Program and the Cervical Cancer Project will assess the implementation of cervical image capture with machine learning for cancer diagnoses and management. SA-5: Examine the epidemiology of NCD comorbidities and ART complications with a focus on the oldest and youngest-age groups affected by HIV. The multi-regional Sentinel Research Network (SRN) will address non-communicable diseases in people living with HIV (PLHIV) > 40 years and the regional MANGO Cohort will address complications of ART/HIV exposure on HIV-Exposed Infants.

# data[].attributes.title
East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional Consortium

# data[].attributes.funder_divisions[]
National Institute of Allergy and Infectious Diseases (NIAID)

# data[].attributes.abstract
Project Summary/Abstract: Our primary goal continues to be the provision of answers to questions that clinicians, governments, programs and international organizations consider central to the evolution and sustainability of their long term HIV care and treatment strategies for achieving the UNAIDS 2030 targets of 95-95-95 in the midst of the SARS-CoV-2 pandemic and changes in public health funding priorities. Our central hypothesis is that retention in the HIV care cascade and treatment outcomes are influenced by patient-level demographic, clinical, developmental, and behavioral factors, as well as, factors within the ambient health care and broader contextual environment. We will leverage our strengths, including robust working relationships with HIV treatment programs, a substantial harmonized regional database, plus broad experience in sampling-based methodologies and novel analytical approaches. Over the course of this research we will: SA-1: Describe movement through the HIV care cascade with a focus on identifying broader and health care environment contextual factors that influence optimal retention in care and viral suppression, in the face of global disruption due to the COVID-19 pandemic and changes in donor funding priorities. The Post COVID-19 Double-Sampling Cohort (Post COVID) will address the impact of broader contextual factors (COVID-19) while the Telehealth and Structural Adaptations project will address the impact of health care structure. SA-2: Examine the impact of developmental stage and behavioral factors on retention in the cascade and subsequent outcomes. The multiregional Adolescent and Young Adult Network of IeDEA (AYANI) and regional Measuring Adverse Pregnancy and Newborn Congenital Outcomes (MANGO) cohorts will assess the impact of developmental stage on the cascade, while the Syndemics cohort will address the impact of mental health on the cascade.SA- 3: Examine the immediate and long-term outcomes of people diagnosed with Tuberculosis (TB) with a focus on identifying and addressing factors associated with patient outcomes. The multiregional TB Sentinel Research Network (TB-SRN) will focus on understanding TB outcomes and long-term pulmonary complications including associated factors. SA-4: Explore the use of new technologies, including eHealth and machine (deep) learning to diagnose and manage HIV-associated cancers with a focus on Kaposi’s Sarcoma (KS) and Cervical Cancer. The KS Project will assess implementation of a Dermatology Telehealth Program and the Cervical Cancer Project will assess the implementation of cervical image capture with machine learning for cancer diagnoses and management. SA-5: Examine the epidemiology of NCD comorbidities and ART complications with a focus on the oldest and youngest-age groups affected by HIV. The multi-regional Sentinel Research Network (SRN) will address non-communicable diseases in people living with HIV (PLHIV) > 40 years and the regional MANGO Cohort will address complications of ART/HIV exposure on HIV-Exposed Infants.